Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CTSK | P43235 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL470552 | 1.00 | HSD11B1 (0.68) | HSD11B1CYP2C9CTSKCA1CA2 | |
| SCHEMBL5822208 | 1.00 | HSD11B1 (0.68) | HSD11B1CYP2C9CTSKCA1CA2 | |
| SCHEMBL1782544 | 0.92 | HSD11B1 (0.60) | HSD11B1CYP2C9CTSKCA1CA2 | |
| SCHEMBL2037731 | 0.92 | HSD11B1 (0.60) | HSD11B1CYP2C9CTSKCA1CA2 | |
| SCHEMBL22680068 | 0.92 | HSD11B1 (0.60) | HSD11B1CYP2C9CTSKCA1CA2 | |
| SCHEMBL17545919 | 0.91 | CA1 (0.71) | HSD11B1CYP2C9CTSKCA1CA2 | |
| SCHEMBL18926997 | 0.90 | EPHX1 (0.70) | HSD11B1CYP2C9CTSKCA1CA2 | |
| SCHEMBL15084717 | 0.90 | HSD11B1 (0.57) | HSD11B1CYP2C9CTSKCA1CA2 | |
| SCHEMBL15084767 | 0.90 | HSD11B1 (0.57) | HSD11B1CYP2C9CTSKCA1CA2 | |
| SCHEMBL655025 | 0.88 | HSD11B1 (0.62) | HSD11B1CYP2C9CTSKCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-2831075-B1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-1689752-B1 | PYRAZOLOPYRIMIDINES | PFIZER LTD (GB) | 2008-02-27 | — | — | EP | disclosed |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| US-7262192-B2 | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors | PFIZER INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262192-B2 | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors | PFIZER INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070105877-A1 | Pyrazolopyrimidines | PFIZER INC | 2007-05-10 | — | — | US | disclosed |
| US-20070105877-A1 | Pyrazolopyrimidines | PFIZER INC | 2007-05-10 | — | — | US | disclosed |
| CN-1780841-A | 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the traetment of hypertension | PFIZER LTD (GB) | 2006-05-31 | — | — | CN | disclosed |
| WO-2005049617-A1 | PYRAZOLOPYRIMIDINES | PFIZER LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| US-5496951-A | 1-CYCLOPROPYL-6-FLUORO-8-FLUORINATED METHOXY COMPOUNDS INCLUDING BORON DIFLUORIDE CHELATE; CHEMICAL INTERMEDIATES AND ANTIBACTERIAL AGENTS | SANKYO COMPANY, LIMITED (JP) | 1996-03-05 | — | — | US | disclosed |
| US-5436367-A | 3, 4-difluorobenzoic acid derivatives | SANKO COMPANY, LIMITED (JP) | 1995-07-25 | — | — | US | disclosed |
| US-5348961-A | Antibacterial agents | SANKYO COMPANY LIMITED (JP) | 1994-09-20 | — | — | US | disclosed |
| EP-0610958-A2 | Intermediates in the preparation of 4-oxoquinoline-3-carboxylic acid derivatives | UBE INDUSTRIES, LTD. (JP) | 1994-08-17 | — | — | EP | disclosed |
| US-5073556-A | Bactericides | SANKYO COMPANY LIMITED (JP) | 1991-12-17 | — | — | US | disclosed |
| EP-0352123-A2 | 4-Oxoquinoline-3-carboxylic acid derivatives, their preparation and their use | UBE INDUSTRIES LIMITED (JP) | 1990-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105877-A1 | Pyrazolopyrimidines | DPYD, CYP2D6, TPMT | HSD11B1 1641/4885CYP2C9 37/4885CTSK 3171/4885 |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | ABCB11, PCSK9, SLC10A1 | HSD11B1 491/4885CYP2C9 76/4885CTSK 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.